<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02146547</url>
  </required_header>
  <id_info>
    <org_study_id>ABR49490</org_study_id>
    <nct_id>NCT02146547</nct_id>
  </id_info>
  <brief_title>European Long-acting Antipsychotics in Schizophrenia Trial</brief_title>
  <acronym>EULAST</acronym>
  <official_title>European Long-acting Antipsychotics in Schizophrenia Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Schizophrenia is a chronic psychiatric illness with periods of remission and relapse.
      Patients vary in the frequency and severity of relapse, time until relapse and time in
      remission. Discontinuation of antipsychotic medication is by far the most important reason
      for relapse. A possible method to optimize medication adherence is to treat patients with
      long-term, depot medication rather than oral medication. However, despite its apparent
      &quot;common sense&quot; this approach has neither been universally accepted by practicing
      psychiatrists nor unequivocally demonstrated in clinical trials. Therefore, in this study we
      aim to investigate possible advantages of depot medication over oral antipsychotics in an
      independently designed and conducted, randomized, pragmatic trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It remains unclear if depot medication can reduce relapse rates and improve clinical outcome
      when offered to all patients in need of continuation treatment with antipsychotics. Before we
      can conclude whether or not all schizophrenia patients could benefit from a switch to depot
      formulations, several questions remain to be answered. Is depot medication associated with
      better continuation rates and outcome? How are depot medications tolerated as compared to
      oral medication? In order to clarify these important issues we aim to perform a large
      multi-center trial in which schizophrenia patients in need of continuous treatment who are
      randomized 1:1:1:1 to two different depot preparations or to two different oral medications.

      In this pragmatic, randomized, open label, multicenter, multinational comparative trial,
      schizophrenic patients aged 18 years or older, having experienced the first psychosis between
      6 months and 7 years ago,with an indication (patient or physician initiated) to receive
      medication or to switch to another antipsychotic drug, will enter the study.

      The study duration will be one month for the medication switch and then a follow-up of 18
      months. Patients having refused to take part in the study will be asked to give consent and
      participate in a naturalistic follow-up, during which they will be followed with the Clinical
      Global Impression list (CGI) as closely related to the study schedule as possible, unless
      they also refuse this.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All cause discontinuation rates</measure>
    <time_frame>18 months</time_frame>
    <description>Compare all cause discontinuation rates in patients with schizophrenia randomized to oral antipsychotic medications (i.e., aripiprazole or paliperidone) versus depot antipsychotic medications (i.e., paliperidone palmitate or aripiprazole depot).
Discontinuation consist of (multiple options are possible):
the allocated treatment is stopped or used at doses outside the allowed range.
medication is switched or augmented with another antipsychotic after visit 4 for more than 1 month continuously or for more than 3 months cumulative over the 18 months of the trial.
a patient misses a monthly visit and does not show up after reminding him
patient withdraws consent for the study.
clinician decision to withdraw the patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective Wellbeing under Neuroleptics</measure>
    <time_frame>18 months</time_frame>
    <description>Change from baseline in Subjective Wellbeing under Neuroleptics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQoL quality of life scale</measure>
    <time_frame>18 months</time_frame>
    <description>Change from baseline in EuroQoL quality of life scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects assessment</measure>
    <time_frame>18 months</time_frame>
    <description>Change from baseline in SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS) and the Abnormal and Involuntary Movement Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of cognitive functioning</measure>
    <time_frame>18 months</time_frame>
    <description>Compare the combined oral medication group with the combined depot treatment arms regarding cognitive functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Positive and Negative Symptom Scale</measure>
    <time_frame>18 months</time_frame>
    <description>Compare the combined oral medication group with the combined depot treatment arms regarding changes in different dimensions of psychopathology of schizophrenia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Personal and Social Performance Scale</measure>
    <time_frame>18 months</time_frame>
    <description>Compare the combined oral medication group with the combined depot</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of Personal and Social Performance Scale</measure>
    <time_frame>Baseline until 18 months</time_frame>
    <description>Compare the combined oral medication group with the combined depot</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Comparison between depot arms and the oral treatment arms on the one side</measure>
    <time_frame>18 months</time_frame>
    <description>The comparisons will also be made between the depot arms and the oral treatment arms on the one side and the patients who are followed up naturalistically.Depot arms are compared regarding augmentation with oral antipsychotics after visit 4.</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment success regarding outcomes in patients who have not given consent for the main trial</measure>
    <time_frame>up to 18 months</time_frame>
    <description>compare treatment success regarding the outcomes mentioned above to those achieved in a group of patients who did not agree to participate in the trial but could be followed up with the CGI.</description>
  </other_outcome>
  <other_outcome>
    <measure>Compare side effects between combined oral medication groups &amp; combined depot treatment</measure>
    <time_frame>18 months</time_frame>
    <description>Compare side effects and general wellbeing under antipsychotic medication between the combined oral medication groups with the combined depot treatment arms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Immune parameters</measure>
    <time_frame>18 months</time_frame>
    <description>Associations between immune parameters on the one hand, and primary as well as secondary outcome measures on the other.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>aripiprazole oral</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the recommended starting dose for aripiprazole is 10 or 15 mg/day with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to meals.Aripiprazole is effective in a dose range of 10 to 30 mg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aripiprazole depot</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The recommended starting and maintenance dose of aripiprazole depot is 400 mg. Titration of the dose of this medicinal product is not required. It should be administered once monthly as a single injection (no sooner than 26 days after the previous injection).
After the first injection, treatment with 10 mg to 20 mg oral aripiprazole should be continued for 14 consecutive days to maintain therapeutic aripiprazole concentrations during initiation of therapy.
If there are adverse reactions with the 400 mg dosage, reduction of the dose to 300 mg once monthly should be considered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paliperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The recommended dose of paliperidone for the treatment of schizophrenia is 6 mg once daily, administered in the morning. Initial dose titration is not required. Some patients may benefit from lower or higher doses within the recommended range of 3 mg to 12 mg once daily. Dosage adjustment, if indicated, should occur only after clinical reassessment. When dose increases are indicated, increments of 3 mg/day are recommended and generally should occur at intervals of more than 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paliperidone palmitate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The first two administrations of paliperidone palmitate (150 mg at visit 3 and 100 mg one week later) need to be administered deep into the deltoid muscle in order to attain therapeutic concentrations rapidly. No oral supplementation with paliperidone is needed. Following the second dose, monthly maintenance doses can be administered in either the deltoid or gluteal muscle. The recommended monthly maintenance dose is 75 mg, although some patients may benefit from lower doses within the recommended range of 25 to 150 mg based on individual patient tolerability and/or efficacy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Administration in once-a-day schedule without regard to meals.</description>
    <arm_group_label>aripiprazole oral</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole depot</intervention_name>
    <description>Abilify Maintena is an intramuscular (IM) depot formulation of oral aripiprazole. It provides the efficacy and safety profile of oral aripiprazole in a once-monthly injection.</description>
    <arm_group_label>Aripiprazole depot</arm_group_label>
    <other_name>Abilify maintena</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paliperidone</intervention_name>
    <description>Administration once a day orally standardised in relation to food intake.</description>
    <arm_group_label>Paliperidone</arm_group_label>
    <other_name>Invega</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paliperidone palmitate</intervention_name>
    <description>In selected patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilization with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable is needed.</description>
    <arm_group_label>Paliperidone palmitate</arm_group_label>
    <other_name>Xeplion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of schizophrenia as defined by DSM-IV-R (Diagnostic and Statistical Manual)
             as determined by the M.I.N.I.plus

          2. Age 18 or older.

          3. 3. The first psychosis occurred at least 6 months and no more than 7 years ago.*

          4. If patients are using an antipsychotic drug, a medication switch is currently under
             consideration.

          5. Capable of providing written informed consent

               -  Time of first psychosis is defined as the first contact with a health care
                  professional in relation to psychotic symptoms.

        Exclusion Criteria:

          1. Intolerance / hypersensitivity to both* of the drugs (including active substances,
             metabolites and excipients) in this study including oral paliperidone and aripiprazole
             and/or hypersensitivity to risperidone.

          2. Pregnancy or lactation.

          3. Patients who are currently using clozapine.

          4. Patients who do not fully comprehend the purpose or are not competent to make a
             rational decision whether or not to participate.

          5. Patients with a documented history of intolerance to both* of the study medications
             and/or a documented history of non-response to a treatment with both* study drugs of
             at least 6 weeks within the registered dose range.7. Patients who have been treated
             with an investigational drug within 30 days prior to screening.

        8. Simultaneous participation in another intervention study (neither medication or
        psychosocial intervention).

        * If intolerance/hypersensitivity or non-response in the past to one of the compounds is
        documented, the patient can still participate; however, randomization will take place by
        blocking that specific compound. That is, the patient will be randomized on either the oral
        or the depot arm of the other compound. This procedure of blocking one compound is also
        accepted for patients who have experienced too many side effects to one of the compounds in
        the past, as documented in the patient's medical record. The decision to block that
        specific compound for randomization in these cases is up to the discretion of the treating
        physician who will carefully balance this decision and clearly document it in the medical
        record.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rene S Kahn, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Fleischhacker, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Biological Psychiatry, Innsbruck University Clinics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Davidson, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiatry, Sackler Faculty of Medicine, Tel Aviv University, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rene Kahn, professor</last_name>
    <phone>+31 887556025</phone>
    <email>R.Kahn@umcutrecht.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leonie Willebrands, project manager</last_name>
    <phone>+31 887553227</phone>
    <email>eulast@umcutrecht.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Biological Psychiatry, Innsbruck University Clinics</name>
      <address>
        <city>Innsbruck</city>
        <state>Anichstrasse 35</state>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Hofer, Ass Prof Dr</last_name>
      <email>a.hofer@i-med.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Psychosoziale Dienste</name>
      <address>
        <city>Vienna</city>
        <state>Modecenterstraße</state>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Psota, Dr.</last_name>
      <email>chapost@psd-wien.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ZNA, department of Psychiatry, locatie Stuivenberg</name>
      <address>
        <city>Antwerp</city>
        <state>Lange Beeldekensstraat 267</state>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jurjen Luykx, Dr.</last_name>
      <email>Jurjen.Luykx@zna.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Psychiatrisch Ziekenhuis Duffel</name>
      <address>
        <city>Antwerp</city>
        <state>Stationsstraat 22C</state>
        <zip>2570</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Sabbe, Prof. Dr.</last_name>
      <email>bernard.sabbe@emmaus.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Neurology and Psychiatry 'St. Naum' 1</name>
      <address>
        <city>Sofia</city>
        <state>Louben Roussev Str.</state>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luchezar Hranov, Ass Prof Dr</last_name>
      <email>lucho.hranov@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Psychiatrická klinika LF UK</name>
      <address>
        <city>Hradec Králové</city>
        <state>Fakultní Nemocnice</state>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Köhler, Dr.</last_name>
      <email>kohlerr@lfhk.cuni.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Ustohal</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Libor Ustohal, Dr.</last_name>
      <email>Ustohal.libor@fnbrno.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Mohr</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Mohr, Dr.</last_name>
      <email>Pavel.Mohr@nudz.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Neuropsychiatric Research</name>
      <address>
        <city>Glostrup</city>
        <state>Ndr. Ringvej</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Psychiatrie und Psychotherapie der Heinrich-Heine-Universität</name>
      <address>
        <city>Düsseldorf</city>
        <state>Bergische Landstraße 2</state>
        <zip>40629</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Cordes, Dr.</last_name>
      <email>joachim.cordes@lvr.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Technische Universität München (TUM</name>
      <address>
        <city>München,</city>
        <state>Ismaningerstrasse 22</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Leucht, Prof Dr med</last_name>
      <email>stefan.leucht@lrz.tum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Psychiatrie, Psychotherapie und Psychosomatik der Martin-Luther-Universität</name>
      <address>
        <city>Halle</city>
        <state>Julius-Kühn-Straße 7</state>
        <zip>06112</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Rujescu, Prof. Dr.</last_name>
      <email>dan.rujescu@uk-halle.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry and Psychotherapy</name>
      <address>
        <city>München</city>
        <state>Nussbaumstrasse 7</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alkomiet Hasan, PD Dr.</last_name>
      <email>alkomiet.hasan@med.uni-muenchen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National and Kapodistrian University of Athens Medical School, Eginition Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikos Stefanis, Prof. Dr.</last_name>
      <email>nistefan@med.uoa.gr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Csekey</name>
      <address>
        <city>Balassagyarmat</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laslo Csekey, Dr.</last_name>
      <email>1pszich@korhaz.t-online.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry and Psychotherapy, Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istvan Bitter, Prof. Dr.</last_name>
      <email>bitter.istvan@med.semmelweis-univ.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abravanel Mental Health Center</name>
      <address>
        <city>Bat-Yam</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Be'er-Ness Mental Health Center</name>
      <address>
        <city>Be'er Ya'aqov</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Kupchik, Dr.</last_name>
      <email>marinakup@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Jerusalem Mental Health Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Teitelbaum, Dr.</last_name>
      <email>alex.teitelbaum@psjer.health.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lev-Hasharon Medical Center for Mental Health</name>
      <address>
        <city>Pardesiyya</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Oyffe, Dr.</last_name>
      <email>ioyffe@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Geha Medical Health Center</name>
      <address>
        <city>Petach-Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Weiser, Profesor,Dr.</last_name>
      <email>mweiser@013net.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry, University of Naples SUN</name>
      <address>
        <city>Naples</city>
        <state>Largo Madonna Delle Grazie 1</state>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvana Galderisi, Prof. Dr.</last_name>
      <email>Silvana.Galderisi@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Torino. Dipartimento di Neuroscienze</name>
      <address>
        <city>Turin</city>
        <state>Sezione Di Psichiatriavia Cherasco, 11</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Rocca, MD</last_name>
      <email>paola.rocca@unito.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Servizio Psichiatrico Universitario di Diagnosi e Cura. Presidio Ospedaliero &quot;San Salvatore&quot; Università degli Studi dell'Aquila.</name>
      <address>
        <city>L'Aquila</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Rossi, Dr.</last_name>
      <email>alessandro.rossi@cc.univaq.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Helse Bergen HF Haukeland University Hospital, Division of Psychiatry</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Johnsen, Dr.</last_name>
      <email>erik.johnsen@helse-bergen.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital avd Østmarka / INM NTNU</name>
      <address>
        <city>Trondheim</city>
        <zip>7441</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Solveig Klebo Reitan, Ass Prof Dr</last_name>
      <email>Solveig.Klebo.Reitan@stolav.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instytut psychiatrii i neurologii</name>
      <address>
        <city>Warsaw</city>
        <state>Sobieskiego 9</state>
        <zip>02-957</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Jarema, Prof dr med</last_name>
      <email>jarema@ipin.edu.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>II Klinika Psychiatrii Uniwersytet Medyczny w Lublinie</name>
      <address>
        <city>Lublin</city>
        <state>Ul. Głuska 1</state>
        <zip>20-439</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcin Olajossy, dr. med.</last_name>
      <email>olajossy@o2.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Arad - Clinica de Psihiatrie</name>
      <address>
        <city>Arad</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie &quot;Prof. Dr. Alexandru Obregia&quot;</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie &quot;Prof. Dr. Alexandru Obregia</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Spitalul de Psihiatrie si pentru Masuri de Siguranta, Sapoca, Buzau</name>
      <address>
        <city>Buzău</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Neuropsihiatrie Craiova</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sitalul Clinic Judetean Mures</name>
      <address>
        <city>Targu Mureş</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurel Nirestean, prof.dr.</last_name>
      <phone>0746030006</phone>
      <email>aurelnirestean@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona. Unidad de Esquizofrenia</name>
      <address>
        <city>Barcelona</city>
        <state>C/Villarroel, 170. Escalera12, Planta 0</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla, Servicio de Psiquiatría</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benedicto Crespo Facorro, Dr.</last_name>
      <email>benedicto.crespo@unican.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Facultad de Medicina Center</name>
      <address>
        <city>Oviedo</city>
        <state>Julián Clavería S/n</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio Bobes, Prof. Dr.</last_name>
      <email>bobes@uniovi.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Child and Adolescent Psychiatry Department. Hospital General Universitario Gregorio Marañón. Servicio Madrileño de Salud</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Covadonga Martínez, Prof. Dr.</last_name>
      <email>covadonga.martinez@iisgm.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West London Mental Health Trust. East Recovery Team</name>
      <address>
        <city>London</city>
        <state>Avenue House 43-47 Avenue Road</state>
        <zip>W38NJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Greater Manchester West Mental Health NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <state>Crowell House, Cromwell Road</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Haddad, Dr.</last_name>
      <email>peter.haddad@gmw.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Edmund Ward, St Martins Hospital Littlebourne Road Canterbury</name>
      <address>
        <city>Kent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Umoh, Dr.</last_name>
      <email>ekwere.umoh@kmpt.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imperial College, Centre for Mental Health, Faculty of Medicine,</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Tees, Ask and Wearvalleys</name>
      <address>
        <city>Middlesbrough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Mayfield, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northumberland</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Keown, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oxford Health NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Geddes, Prof. Dr.</last_name>
      <email>john.geddes@psych.ox.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Surrey and Borders Partnership NHS Foundation Trust</name>
      <address>
        <city>Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramin Nilforooshan, Dr.</last_name>
      <email>Ramin.Nilforooshan@sabp.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2014</study_first_submitted>
  <study_first_submitted_qc>May 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2014</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Rene Kahn</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>depot, oral, antipsychotics, paliperidone, aripiprazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Paliperidone Palmitate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

